Skip to main
IMMP

Immutep Ltd (IMMP) Stock Forecast & Price Target

Immutep Ltd (IMMP) Analyst Ratings

Based on 2 analyst ratings
Hold
Strong Buy 0%
Buy 50%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Immutep Ltd is advancing its lead product candidate, eftilagimod alfa (efti), through a registrational Phase three clinical trial for first-line non-small cell lung cancer, where efti has demonstrated significant efficacy, particularly in patients with less responsive tumor types, increasing overall response rates substantially. The company's robust patent portfolio and the product's compatibility with existing PD-(L)1 therapies present opportunities for significant market expansion and the establishment of new treatment franchises. Such advancements underscore a positive outlook for Immutep's stock, reflecting the potential for enhanced patient outcomes and commercial success in the oncology sector.

Bears say

Immutep Ltd faces a negative outlook primarily due to concerns regarding the underwhelming clinical results of its lead product candidate, eftilagimod alfa (efti), which has led to a significant reduction in the projected probability of success in non-small cell lung cancer (NSCLC) to just 30%. Additionally, the company's focus on LAG-3 antagonists, which have historically shown mixed results in lung cancer, contributes to skepticism about their potential to be transformative in this treatment landscape. Furthermore, lower efficacy outcomes related to the increased proportion of patients with low tumor proportion score (TPS) seen in the ongoing INSIGHT-003 trial further diminish confidence in the commercial viability of Immutep's therapies.

Immutep Ltd (IMMP) has been analyzed by 2 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 50% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immutep Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immutep Ltd (IMMP) Forecast

Analysts have given Immutep Ltd (IMMP) a Hold based on their latest research and market trends.

According to 2 analysts, Immutep Ltd (IMMP) has a Hold consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immutep Ltd (IMMP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.